AstraZeneca India and 4baseCare to enhance access to genomic testing for cancer patients

As a part of the collaboration, AstraZeneca and 4baseCare will work with the oncologist community to support patients by providing these services locally

4baseCare has announced a collaboration with AstraZeneca India. Under this collaboration, the two organisations will support advanced-stage cancer patients with targeted therapy options using affordable genomic solutions.

As a part of the collaboration, AstraZeneca and 4baseCare will work with the oncologist community to support patients by providing these services locally and also at a low cost ultimately increasing the chances of identifying optimal treatment options thereby improving clinical outcomes.

According to a report by ICMR on the ‘Burden of cancers in India’, seven cancers accounted for more than 40% of the total disease burden; lung and breast cancer being the highest. The number of Indians suffering from cancer is projected to increase to 29.8 million in 2025 from 26.7 million in 2021. Given the advancement of technology in current times, patients have an opportunity to benefit significantly from various new age strategies including ‘Precision Oncology’.  It helps provide targeted therapy to patients by identifying which drugs would work best on which patient depending upon the unique biology of a patient’s disease. Genomics-based molecular profiling is the bedrock of targeted therapy and has proved to be a life-saving diagnostics tool as it helps identify the best medical intervention path while treating a patient.

4baseCare recently launched another gene panel called TARGT IndieGene panel which is a population-specific tumor gene panel derived from Whole Exome and Whole Transcriptome data from over 1,500 cancer patients across 28 different cancer types.